BioCentury | Jan 20, 2021
Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...
BioCentury | Jan 8, 2021
Emerging Company Profile

Impact founder Hood launches Endeavor with $62M to address pulmonary diseases

Endeavor launched Thursday with $62 million from a series A financing round led by Omega Funds and Longitude Capital to treat pulmonary diseases, starting with a hedgehog pathway inhibitor in-licensed from Eli Lilly. John Hood,...
BioCentury | Dec 31, 2020

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

Covaxx licenses COVID vaccine to Aurobindo Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one...
BioCentury | Dec 16, 2020

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

Four months after Jyseleca’s surprise setback at FDA, Gilead and Galapagos are abandoning U.S. development of the therapy that was once the centerpiece of a $5 billion deal between the companies.  ...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...oral JAK-1/JAK-2 inhibitor also failed to lower mortality and time to recovery.Olumiant baricitinib, another oral JAK-1/JAK-2...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...ulcerative colitis and the Phase IIIb Heads Up study for moderate-to-severe atopic dermatitis. The oral JAK-1...
...peptideGLP-1 – Glucagon-like peptide 1HER2 (EGFR2; ErbB2; neu) – Epidermal growth factor receptor 2JAK-1Janus kinase-1 LAG3...
BioCentury | Dec 12, 2020

CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment.  The committee also...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 30, 2020

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
Items per page:
1 - 10 of 877